10 completed. 10 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 10 |
| Phase 3 | 1 | Completed 1 |
Follow Hemolysis: new trials by email Literature Review of Hemolysis trials Research Report on Hemolysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease Etavopivat tablets - Sickle Cell Disease, Thalassemia | Phase 2 | Completed | Forma Therapeutics, Inc. | 53 | 2022-03-28 | 2025-12-16 |
| Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria LNP023 - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Novartis Pharmaceuticals | 13 | 2019-04-05 | 2024-06-18 |
| A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH Pegcetacoplan - PNH | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 4 | 2018-08-16 | 2020-12-22 |
| Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) iptacopan, Standard of Care - Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis | Phase 2 | Completed | Novartis Pharmaceuticals | 16 | 2018-04-09 | 2024-06-12 |
| Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease Bendamustine, Rituximab - Cold Agglutinin Disease, Autoimmune Hemolytic Anemia | Phase 2 | Completed | Helse Fonna | 43 | 2013-01-01 | 2017-01-09 |
| Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease Conditioning Regimen with Bone Marrow Transplant - Sickle Cell Disease | Phase 2 | Completed | Emory University | 22 | 2012-03-01 | 2017-11-21 |
| Therapy of Chronic Cold Agglutinin Disease With Eculizumab Eculizumab - Cold Agglutinin Disease | Phase 2 | Completed | University Hospital, Essen | 13 | 2011-01-01 | 2017-07-19 |
| Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias Alemtuzumab, Rituximab - Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune | Phase 2 / Phase 3 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 19 | 2008-08-01 | 2010-08-30 |
| S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C Peginterferon alfa-2a, Ribavirin, S-adenosyl methionine for Chronic Liver Disease - Chronic Hepatitis C | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 24 | 2007-05-01 | 2013-07-05 |
| Therapy for Chronic Cold Agglutinin Disease Rituximab, Fludarabine - Cold Agglutinin Disease | Phase 2 | Completed | University of Bergen | 30 | 2005-06-01 | 2010-06-22 |
Anemia (6) · Anemia, Hemolytic, Autoimmune (4) · Hematologic Diseases (3) · Hemoglobinuria, Paroxysmal (3) · Anemia, Sickle Cell (2) · Genetic Diseases, Inborn (2) · Anemia, Hemolytic (1) · Hemoglobinopathies (1) · Hemoglobinuria (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Lymphoproliferative Disorders (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Sickle Cell Trait (1)
Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Hemic and Lymphatic Diseases (9) · Anemia, Hemolytic (8) · Hematologic Diseases (6) · Autoimmune Diseases (4) · Immune System Diseases (4) · Anemia (3) · Bone Marrow Diseases (3) · Myelodysplastic Syndromes (3) · Anemia, Hemolytic, Congenital (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Signs and Symptoms (2) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1)
Rituximab (3) · fludarabine (2) · iptacopan (2) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Bendamustine Hydrochloride (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Ribavirin (1) · S-Adenosylmethionine (1) · Standard of Care (1) · Transplantation Conditioning (1) · eculizumab (1) · fludarabine phosphate (1) · pegcetacoplan (1)
Novartis Pharmaceuticals (2) · Apellis Pharmaceuticals, Inc. (1) · Emory University (1) · Forma Therapeutics, Inc. (1) · Helse Fonna (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · University Hospital, Essen (1) · University of Bergen (1)
United States (3) · Germany (2) · Italy (2) · Norway (2) · Bulgaria (1) · Canada (1) · Denmark (1) · Egypt (1) · Finland (1) · France (1) · Lebanon (1) · Malaysia (1) · Mexico (1) · Russia (1) · Serbia (1)
Geir E Tjonnfjord, MD, PhD (2) · Sigbjorn Berentsen, MD, PhD (2) · Alexander Roeth, MD (1) · David Gomez-Almaguer, MD (1) · Elling Ulvestad, MD, PhD (1) · Federico Grossi, MD, PhD (1) · Henrik Birgens, MD, PhD (1) · Jay Hoofnagle, MD (1) · Lakshmanan Krishnamurti, MD (1) · Markku Oksman, MD (1)
PMID 20634373, PMID 20841509, PMID 20854821, PMID 28533306, PMID 30291112, PMID 33765419, PMID 35561315, PMID 35869170
2009 (1), 2017 (1), R34HL108761 (1)